Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

NCT05239650 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

CRC

Interventions

DRUG: HLX07
DRUG: HLX10
DRUG: mFOLFOX6

Sponsor

Shanghai Henlius Biotech